CervoMed (CRVO) News Today $2.11 0.00 (0.00%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period CervoMed downgraded to Neutral from Buy at H.C. WainwrightDecember 17, 2024 | markets.businessinsider.comHC Wainwright & Co. Downgrades CervoMed (CRVO)December 17, 2024 | msn.comCervoMed (CRVO) was downgraded to a Hold Rating at H.C. WainwrightDecember 17, 2024 | markets.businessinsider.comCervoMed announces inducement grants under Nasdaq lisitng ruleDecember 13, 2024 | markets.businessinsider.comCervoMed Inc.: CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 12, 2024 | finanznachrichten.deCervoMed price target lowered to $12 from $65 at CanaccordDecember 12, 2024 | markets.businessinsider.comCervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 12, 2024 | globenewswire.comMorgan Stanley downgrades CervoMed (CRVO) to a SellDecember 12, 2024 | markets.businessinsider.comChardan Capital Downgrades CervoMed (CRVO)December 12, 2024 | msn.comCervoMed announces RewinD-LB Phase 2b did not meet primary endpointDecember 11, 2024 | finance.yahoo.comCervoMed’s stock craters 77% after failed trial of treatment for rare brain diseaseDecember 11, 2024 | marketwatch.comCervoMed (NASDAQ:CRVO) Stock Quotes, Forecast and News SummaryDecember 11, 2024 | benzinga.comJones Trading Downgrades CervoMed (CRVO)December 11, 2024 | msn.comD. Boral Capital Downgrades CervoMed (CRVO)December 11, 2024 | msn.comCervoMed's dementia drug fails to meet mid-stage trial goalsDecember 10, 2024 | reuters.comCervoMed Faces Setback in Phase 2b TrialDecember 10, 2024 | tipranks.comCervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy BodiesDecember 10, 2024 | globenewswire.comHC Wainwright Forecasts CervoMed FY2024 EarningsCervoMed Inc. (NASDAQ:CRVO - Free Report) - Equities research analysts at HC Wainwright issued their FY2024 EPS estimates for CervoMed in a research report issued on Thursday, December 5th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($1.76) for theDecember 9, 2024 | marketbeat.comRoth MKM Initiates Coverage of CervoMed (CRVO) with Buy RecommendationDecember 6, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of CervoMed (CRVO) with Buy RecommendationDecember 6, 2024 | msn.comCervoMed (NASDAQ:CRVO) Coverage Initiated by Analysts at Roth MkmRoth Mkm began coverage on shares of CervoMed in a research report on Friday. They set a "buy" rating and a $45.00 target price on the stock.December 6, 2024 | marketbeat.comQ4 Earnings Forecast for CervoMed Issued By HC WainwrightCervoMed Inc. (NASDAQ:CRVO - Free Report) - Stock analysts at HC Wainwright issued their Q4 2024 earnings per share estimates for CervoMed in a research report issued on Thursday, December 5th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of ($0.53)December 6, 2024 | marketbeat.comCervoMed Enhances Transparency with Key Information AccessDecember 4, 2024 | markets.businessinsider.comCervoMed gains as dementia therapy granted FDA orphan tagNovember 27, 2024 | msn.comCervoMed's (CRVO) Buy Rating Reaffirmed at D. Boral CapitalD. Boral Capital reiterated a "buy" rating and issued a $34.00 target price on shares of CervoMed in a research note on Wednesday.November 27, 2024 | marketbeat.comCervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal DementiaNovember 27, 2024 | globenewswire.comD. Boral Capital Initiates Coverage of CervoMed (CRVO) with Buy RecommendationNovember 20, 2024 | msn.comCervoMed initiated with a Buy at D. Boral CapitalNovember 18, 2024 | markets.businessinsider.comCervoMed Inc. (NASDAQ:CRVO) Short Interest Up 16.5% in OctoberCervoMed Inc. (NASDAQ:CRVO - Get Free Report) was the target of a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 1,480,000 shares, an increase of 16.5% from the October 15th total of 1,270,000 shares. Based on an average daily volume of 81,400 shares, the days-to-cover ratio is presently 18.2 days. Currently, 27.7% of the shares of the stock are sold short.November 16, 2024 | marketbeat.comAnalysts Issue Forecasts for CervoMed FY2024 EarningsCervoMed Inc. (NASDAQ:CRVO - Free Report) - Analysts at Brookline Capital Management dropped their FY2024 EPS estimates for CervoMed in a research report issued on Tuesday, November 12th. Brookline Capital Management analyst T. Bussian now expects that the company will post earnings of ($1.88) peNovember 15, 2024 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Zai Lab (ZLAB), NeuroPace (NPCE) and CervoMed (CRVO)November 14, 2024 | markets.businessinsider.comCervoMed Inc. Reports Increased R&D Expenses Amid Ongoing TrialsNovember 14, 2024 | markets.businessinsider.comCervoMed Inc.: CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesNovember 12, 2024 | finanznachrichten.deCervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesNovember 12, 2024 | globenewswire.comCervoMed Awarded the Prix Galien USA 2024 Prize for Best StartupNovember 8, 2024 | globenewswire.comCervoMed to Participate in Upcoming Investor ConferencesNovember 7, 2024 | globenewswire.comCervoMed announces key takeaways from presentations on neflamapimodNovember 4, 2024 | markets.businessinsider.comCervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)November 4, 2024 | globenewswire.comCervoMed’s Neflamapimod: A Promising Phase 2b Trial for Addressing Dementia with Lewy BodiesNovember 1, 2024 | markets.businessinsider.comCervoMed Inc. (NASDAQ:CRVO) Short Interest UpdateCervoMed Inc. (NASDAQ:CRVO - Get Free Report) was the recipient of a large growth in short interest in October. As of October 15th, there was short interest totalling 1,270,000 shares, a growth of 7.6% from the September 30th total of 1,180,000 shares. Approximately 23.7% of the company's stock are sold short. Based on an average trading volume of 86,700 shares, the short-interest ratio is presently 14.6 days.November 1, 2024 | marketbeat.comCervoMed (NASDAQ:CRVO) Shares Down 3.1% - Time to Sell?CervoMed (NASDAQ:CRVO) Shares Down 3.1% - Here's What HappenedNovember 1, 2024 | marketbeat.comCervoMed to present at International Lewy Body Dementia ConferenceOctober 30, 2024 | markets.businessinsider.comCervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia ConferenceOctober 29, 2024 | globenewswire.comCervoMed Inc. (CRVO)October 20, 2024 | finance.yahoo.comCervoMed Ends $20 Million Stock Sales Agreement with BTIGOctober 4, 2024 | finance.yahoo.comCervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities ConferenceOctober 2, 2024 | globenewswire.comCervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)September 27, 2024 | tmcnet.comArmistice Capital LLC Cuts Holdings in CervoMed Inc. (NASDAQ:CRVO)Armistice Capital LLC trimmed its holdings in shares of CervoMed Inc. (NASDAQ:CRVO - Free Report) by 12.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 640,000 shares of the company's stock after selling 94,36September 26, 2024 | marketbeat.comCervoMed Inc. Forecasted to Earn FY2024 Earnings of ($1.34) Per Share (NASDAQ:CRVO)CervoMed Inc. (NASDAQ:CRVO - Free Report) - Research analysts at Chardan Capital issued their FY2024 earnings estimates for shares of CervoMed in a report released on Wednesday, September 18th. Chardan Capital analyst D. Gataulin anticipates that the company will post earnings of ($1.34) per sharSeptember 23, 2024 | marketbeat.comWith 35% ownership, insiders at CervoMed Inc. (NASDAQ:CRVO) are pretty optimistic and have been buying recentlySeptember 21, 2024 | finance.yahoo.com Get CervoMed News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVO and its competitors with MarketBeat's FREE daily newsletter. Email Address CRVO Media Mentions By Week CRVO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRVO News Sentiment▼1.000.41▲Average Medical News Sentiment CRVO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRVO Articles This Week▼12▲CRVO Articles Average Week Get CervoMed News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OPTN News ELEV News DYAI News ACHL News IVVD News ICCC News CELU News XLO News KZR News VYNE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRVO) was last updated on 1/19/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CervoMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CervoMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
